BACKGROUND: Recent clinical trials from Uganda have shown that the risk of failure following antimalarial therapy varies geographically. We tested the hypothesis that geographic differences in the response to therapy could be explained by differences in the prevalence of known molecular markers of drug resistance. METHODS: Samples from 2084 patients treated withchloroquine (CQ) plus sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) plus SP were tested for the presence of known molecular markers of resistance. Differences in the risk of treatment failure across 6 sites were compared, and age and complexity of infection were controlled for. RESULTS: The prevalence of molecular markers of drug resistance was high at all of the sites: 61%-91% of patients were infected with parasites containing the pfcrt Thr-76 mutation and dhfr/dhps quintuple mutation. The risk of treatment failure decreased with increasing transmission intensity for both CQ plus SP (73% to 19%) and AQ plus SP (38% to 2%). Restricting the analyses to patients infected with parasites containing all 6 mutations of interest did not affect these trends. CONCLUSIONS: The risk of treatment failure was inversely proportional to transmission intensity and was not explained by differences in molecular markers of antimalarial drug resistance. Our findings strongly suggest that geographic differences in response to antimalarial therapy in Uganda are primarily mediated by acquired immunity associated with malaria transmission intensity, rather than by parasite factors.
RCT Entities:
BACKGROUND: Recent clinical trials from Uganda have shown that the risk of failure following antimalarial therapy varies geographically. We tested the hypothesis that geographic differences in the response to therapy could be explained by differences in the prevalence of known molecular markers of drug resistance. METHODS: Samples from 2084 patients treated with chloroquine (CQ) plus sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) plus SP were tested for the presence of known molecular markers of resistance. Differences in the risk of treatment failure across 6 sites were compared, and age and complexity of infection were controlled for. RESULTS: The prevalence of molecular markers of drug resistance was high at all of the sites: 61%-91% of patients were infected with parasites containing the pfcrt Thr-76 mutation and dhfr/dhps quintuple mutation. The risk of treatment failure decreased with increasing transmission intensity for both CQ plus SP (73% to 19%) and AQ plus SP (38% to 2%). Restricting the analyses to patients infected with parasites containing all 6 mutations of interest did not affect these trends. CONCLUSIONS: The risk of treatment failure was inversely proportional to transmission intensity and was not explained by differences in molecular markers of antimalarial drug resistance. Our findings strongly suggest that geographic differences in response to antimalarial therapy in Uganda are primarily mediated by acquired immunity associated with malaria transmission intensity, rather than by parasite factors.
Authors: Alisa P Alker; Jonathan J Juliano; Steven R Meshnick; Andrew Owen; Edwin Ochong; David J Bell; David J Johnson; Umberto d'Alessandro; Modest Mulenga; Sant Muangnoicharoen; J P Van Geertruyden; Peter A Winstanley; Patrick G Bray; Stephen A Ward Journal: Antimicrob Agents Chemother Date: 2009-04 Impact factor: 5.191
Authors: Rosa Elena Mejia Torres; Engels Ilich Banegas; Meisy Mendoza; Cesar Diaz; Sandra Tamara Mancero Bucheli; Gustavo A Fontecha; Md Tauqeer Alam; Ira Goldman; Venkatachalam Udhayakumar; Jose Orlinder Nicolas Zambrano Journal: Am J Trop Med Hyg Date: 2013-03-04 Impact factor: 2.345
Authors: Maryline Bonnet; Ingrid van den Broek; Michel van Herp; Pedro Pablo Palma Urrutia; Chantal van Overmeir; Juliet Kyomuhendo; Célestin Nsibu Ndosimao; Elizabeth Ashley; Jean-Paul Guthmann Journal: Malar J Date: 2009-08-10 Impact factor: 2.979
Authors: Anne F Gasasira; Moses R Kamya; Edwin O Ochong; Neil Vora; Jane Achan; Edwin Charlebois; Theodore Ruel; Fredrick Kateera; Denise N Meya; Diane Havlir; Philip J Rosenthal; Grant Dorsey Journal: Malar J Date: 2010-06-23 Impact factor: 2.979
Authors: José Carlos Sousa-Figueiredo; David Oguttu; Moses Adriko; Fred Besigye; Andrina Nankasi; Moses Arinaitwe; Annet Namukuta; Martha Betson; Narcis B Kabatereine; J Russell Stothard Journal: Malar J Date: 2010-08-27 Impact factor: 2.979
Authors: Joaniter Nankabirwa; Bonnie Cundill; Sian Clarke; Narcis Kabatereine; Philip J Rosenthal; Grant Dorsey; Simon Brooker; Sarah G Staedke Journal: PLoS One Date: 2010-10-19 Impact factor: 3.240
Authors: Patrick M Newman; Humphrey Wanzira; Gabriel Tumwine; Emmanuel Arinaitwe; Sarah Waldman; Jane Achan; Diane Havlir; Philip J Rosenthal; Grant Dorsey; Tamara D Clark; Deborah Cohan Journal: Malar J Date: 2009-11-14 Impact factor: 2.979